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Transplant glomerulopathy (TG) has received much attention
in recent years as a symptom of chronic humoral rejection;
however, many cases lack C4d deposition and/or circulating
donor-specific antibodies (DSAs). To determine the
contribution of other causes, we studied 209 consecutive
renal allograft indication biopsies for chronic allograft
dysfunction, of which 25 met the pathological criteria of TG.
Three partially overlapping etiologies accounted for 21 (84%)
cases: C4d-positive (48%), hepatitis C-positive (36%), and
thrombotic microangiopathy (TMA)-positive (32%) TG. The
majority of patients with confirmed TMA were also hepatitis
C positive, and the majority of hepatitis C-positive patients
had TMA. DSAs were significantly associated with C4d-
positive but not with hepatitis C-positive TG. The prevalence
of hepatitis C was significantly higher in the TG group than in
29 control patients. Within the TG cohort, those who were
hepatitis C-positive developed allograft failure significantly
earlier than hepatitis C-negative patients. Thus, TG is not a
specific diagnosis but a pattern of pathological injury
involving three major overlapping pathways. It is important
to distinguish these mechanisms, as they may have different
prognostic and therapeutic implications.
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Transplant glomerulopathy (TG) is a glomerular lesion
common in long-standing kidney allografts, first described
by Porter et al.1 in 1967 and is characterized by duplication of
glomerular basement membrane. In recent years, it has
received much attention as a manifestation of chronic
humoral rejection (CHR).2,3 The prevalence of TG has been
shown to be approximately 5–10% in all allograft biopsies
performed for clinical indications.4–9 A few contemporary
studies of surveillance and clinical biopsies in kidney
allografts have shown that the incidence of TG is higher
than expected, affecting 4% of conventional transplants at
1 year post-transplant, progressively increasing up to 20% at
5 years.10,11 TG is clinically manifested by low-grade to
nephrotic-range proteinuria with progressive allograft dys-
function and has an extremely poor prognosis, with eventual
graft loss in 40–70% of the affected patients.4–9
The precise pathogenesis of TG remains unclear; theories
include alloreactivity to the donor or chronic infection.
Recent studies increasingly support the association of TG with
circulating donor-specific human leukocyte antigen antibody
(DSA) and/or C4d deposits in peritubular capillaries (PTCs),
suggesting that humoral immune-mediated mechanisms of
tissue injury have a role in the development of TG.9,11–16 In a
series from Vienna, C4d deposition preceded and predicted
development of TG.13 However, a substantial number of cases
of TG have no associated C4d deposits or circulating DSA,
indicating that yet unknown, other non-alloantibody-
mediated processes may be involved in the development of
TG in a significant subset of patients.17–19
Interestingly, the histopathological features of TG, which
include glomerular basement membrane duplication and
increase in mesangial matrix, are reminiscent of membrano-
proliferative glomerulonephritis (MPGN).20 Both TG and
MPGN induce proteinuria and appear similar by light
microscopy. The mesangial and glomerular endocapillary
hypercellularity of MPGN have also been recently described
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in cases of TG.21 However, by immunofluorescence (IF) and
electron microscopy (EM), immune complexes and electron-
dense deposits (subendothelial and/or mesangial) are typi-
cally seen in MPGN but not usually in TG.1,2,4,20,22,23 In the
past few years, MPGN has been clearly associated with
hepatitis C virus (HCV) infection, both in non-transplant
and transplant settings.24–32 The pathogenesis of HCV-
associated glomerular disease involves the formation of
immune complexes within the glomeruli.26–29 However,
immune complexes may be scant or absent in a subgroup
of recipients with chronic glomerular lesions after transplan-
tation because of the immunosuppression, and may render
a clear distinction between TG and MPGN difficult in
most cases.
Owing to the similarities between the histopathological
features of TG and HCV-associated MPGN, a causal
association between TG and HCV infection has been
suggested in a few reports. In 1995, Gallay et al.33 first
suggested a possible association between HCV infection and
TG in two kidney allograft recipients at 3 and 7 years
after transplantation. These authors speculated that some
patients diagnosed with TG may actually have HCV-
associated MPGN. Cosio et al.34 also found an increased
prevalence (33%) of HCV infection in 27 kidney allograft
recipients with TG. In their study, IF and EM were available
in only a minority of cases, and therefore pathological
analysis was limited. Corroborating these findings, in a
recent study of protocol biopsies in kidney allografts,
pretransplant HCV antibody positivity was found to be an
independent risk factor for the development of TG.11
However, the diagnosis of TG in their study was based only
on light microscopy findings. In contrast to the above
findings, Cruzado et al.35 did not find any significant
difference in the prevalence of TG in HCV-positive and
HCV-negative kidney recipients when they included EM
examination in all biopsies.
Another disorder that can produce many of the histo-
logical findings analogous to TG is thrombotic microangio-
pathy (TMA), also initiated by endothelial injury and/or
dysfunction. TMA has usually been associated with calci-
neurin inhibitor toxicity (CNIT) or with CHR in kidney
transplant recipients.36,37 In addition, TMA has also been
identified in cases of HCV.38–40 However, systemic clinico-
pathological studies looking at the association between
TG, TMA, and HCV infection and contribution of these
additional potential causes of TG apart from CHR in kidney
transplant recipients are lacking.
There is an unmet need to better characterize precise
etiology and pathogenesis of TG, as it could contribute to
prevention or interventions to preserve optimal graft
function and survival in patients with this lesion. In this
clinicopathological study with a long-term follow-up,
we aimed to delineate the pathogenesis of TG after
kidney transplantation and sought clinical and pathological
evidence for additional potential causes of TG apart
from CHR.
RESULTS
Clinical features and course of TG
All patients had received ABO-compatible grafts and had a
negative cross-match before transplantation. The mainte-
nance immunosuppressive protocol consisted of cyclospor-
ine, prednisone, and azathioprine (n¼ 21), or prednisone
and azathioprine (n¼ 4). None of these patients received
antibody induction therapy.
The prevalence of TG was 12% (25/209) in all biopsies
performed for evaluation of chronic allograft dysfunction
and/or proteinuria. TG was diagnosed at a median of 66
months (range 6.2–413.3 months) after transplantation, with
a mean serum creatinine at biopsy of 4.4±2.1mg/dl and low-
grade or nephrotic-range proteinuria (43.5 g/24 h). A
significantly higher prevalence of HCV infection was
observed in patients with TG as compared with the 29
control patients with chronic CNIT (36% versus 7%;
P¼ 0.02). All patients were hepatitis B surface antigen
negative. None of the HCVþ patients had received previous
interferon therapy.
Pathology and C4d staining
Three overlapping categories of TG were identified in 21/25
(84%) cases: C4dþTG (12/25; 48%), HCVþTG (9/25; 36%),
and TMAþTG (8/25; 32%). These overlapping features are
illustrated through two-way hierarchical clustering (Figure 1).
A total of 15 cases (60%) had only one of these features,
probably representing an independent cause of TG (9 C4dþ ,
3 HCVþ, and 3 TMAþ ). Six cases (24%) had combinations
of C4dþ and HCVþ or HCVþ and TMA. Four cases (16%)
had no evidence of HCV, CHR, or TMA. Of these, three had
severe hyaline arteriolopathy attributed to CNIT, and there-
fore may have had an element of TMA. The fourth was a graft
that had been in place for 34 years. The majority of the TMA
cases were HCVþ (5/8; 62%) and the majority of HCVþ
cases had TMA (5/9; 56%), suggesting that these are
interrelated.
The pathological features comparing HCVTG with
HCVþTG and also according to the C4d status are
summarized in Table 1. Only 2/9 (22%) HCVþTG cases
had evidence of mesangial hypercellularity as compared
with 11/16 (66%) HCVTG cases (P¼ 0.04). We did not
find any significant differences in presence of mononuclear
cells in the glomeruli or PTC and PTC basement membrane
multilayering when analyzed according to either the HCV
or C4d status. These features were also present in
some HCVþTG cases even in the absence of C4d and/or
DSA.
No significant differences were found in PTC C4d
deposition between HCVTG and HCVþTG patients (9/16,
56% versus 3/9, 33%; P¼nonsignificant). No case of
MPGN in native kidneys had C4d deposits in PTC. Immune
complexes and subendothelial electron-dense deposits were
present in all cases of HCV-associated MPGN in native
kidneys as expected and in none of the TG cases (by definition,
as described in the Materials and Methods section).
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Clinical characteristics of HCVþTG versus HCVTG patients
The two groups of patients were similar with respect to
demographics and baseline characteristics, such as age, race,
gender, donor status (deceased or living donor), number of
retransplants, panel reactive antibodies ‘peak’ and ‘current’ at
the time of transplantation, and human leukocyte antigen
matching. All patients in both groups were followed until
progression to graft failure or death with a functioning graft.
The clinical features of these two groups are compared in
Table 2. A striking observation was that the duration from
transplantation to total graft loss was significantly shorter
in HCVþTG than the HCVTG patients (71.1±52.7 versus
153.7±120.5 months; P¼ 0.03), as also shown by Kaplan–-
Meier survival analyses (Figure 2, P¼ 0.02, log-rank test).
More HCVþTG patients (4/9; 44%) had persistently abnor-
mal liver function tests (defined by elevation of transaminases,
aspartate aminotransferase, and/or alanine aminotransferase,
450U/l on at least two occasions and maintained for more
than 6 months) in contrast to none (0%) in the HCVTG
group, suggesting the presence of chronic liver disease in
HCVþ patients (P¼ 0.01). Complement levels and cryoglob-
ulin measurements were available in three HCVTG patients
and one HCVþTG patient. C3 and C4 values were normal,
except in one HCVTG patient who had low C3 with normal
C4; cryoglobulins were undetectable in all the four patients.
Multivariate analysis showed that the presence of HCV
had the highest likelihood ratio for more rapid progression to
graft failure using both proportional hazards (Cox) and
parametric survival fit methods (likelihood ratio¼ 4.56 and
5.06, and P¼ 0.03 and 0.02, respectively), with the other
factors (C4d and TMA) having likelihood ratios that were
not statistically significant (Table 3).
Donor-specific antibody
Of the 12 TG patients tested in the peri-biopsy period for
circulating DSA, 7/8 C4dþTG patients had positive de novo
DSA (that is, negative pretransplant and positive at the time
of biopsy) compared with 1/4 C4dTG patients (88% versus
25%; Po0.02). Furthermore, eight of nine HCVTG patients
had detectable de novo DSA as compared with none in the
three HCVþTG patients (89% versus 0%, P¼ 0.04). The
information on DSA is displayed in Figure 1.
DISCUSSION
The findings of this study provide further insight into natural












































Figure 1 | The heterogeneity of TG cases is displayed through
two-way hierarchical clustering with regard to the presence
of C4d, DSA, TMA, and HCV. Each line displays a TG case.
The dendrograms on the right show how closely related the cases
are, and the dendrogram on the bottom shows how closely
related the features (C4d, DSA, TMA, and HCV) are.
DSA, donor-specific antibody; HCV, hepatitis C virus; Pos, positive;
NA, not available; Neg, negative; TG, transplant glomerulopathy;
TMA, thrombotic microangiopathy.
Table 1 | Pathological features of patients with TG according to HCV and C4d status
HCVTG (n=16; %) HCV+TG (n=9; %) C4dTG (n=13) C4d+TG (n=12)
GBM duplication (both LM+EM) 16 (100%) 9 (100%) 13 (100%) 12 (100%)
Mesangial hypercellularity 11 (69%)a 2 (22%)a 8 (62%) 5 (42%)
Mononuclear cells in glomerulib (X10 cells/glomerulus) 10/14 (71%) 5/7 (71%) 10/13 (77%) 5/8 (63%)
Mononuclear cells in PTCc (in 410% PTC) 3/13 (23%) 2/7 (29%) 1/12 (8%) 4/8 (50%)
PTCBMML (X3 layers)d 4/8 (50%) 4/4 (100%) 1/3 (33%) 7/9 (78%)
Additional features of TMA (n=8) 3 (19%) 5 (56%) 6 (46%) 2 (17%)
Complement C4d deposits in PTC (n=12) 9 (56%) 3 (33%) 0 12
HCV positivity 0 9 6/13 (46%) 3/12 (25%)
Abbreviations: EM, electron microscopy; GBM, glomerular basement membrane; HCV, hepatitis C virus; LM, light microscopy; PTC, peritubular capillary; PTCBMML, peritubular
capillary basement membrane multilayering; TG, transplant glomerulopathy; TMA, thrombotic microangiopathy.
aP=0.04.
bData could be analyzed in 21/25 cases.
cData could be analyzed in 20/25 cases.
dData could be analyzed in 12/25 cases.
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recipients. We found that TG was associated with a dismal
graft outcome, with a median survival of only 9 months
following the biopsy diagnosis. Pathogenetically, three over-
lapping categories of TG could be identified in a majority
(84%) of patients: C4dþTG (48%), HCVþTG (36%), and
TMAþTG (32%). In a small proportion of patients, none of
these causes could be identified, suggesting that there may be
still unknown factors that have a role in the development of
TG in some patients.
Of particular interest was the striking prevalence of HCV
infection in recipients with TG (36%), which was signifi-
cantly higher than the prevalence seen in the chronic CNIT
control group without TG (7%) or in our overall kidney
transplant population (4.8%).38 These results extend and
confirm previous observations 11,33,34 and suggest a strong
causal association between HCV infection and TG. Further-
more, HCVþTG recipients differed from HCVTG patients
clinically by a significantly more rapid progression to graft
failure after transplantation and increased frequency of
abnormal liver function tests. By multivariate analysis
analyzing the impact of HCV, C4d, and TMA on graft
failure, HCV alone was found to have a highest likelihood
ratio for more rapid progression to graft failure, suggesting
that HCV per se was associated with more rapid graft loss.
We found C4d deposition in PTC in approximately half
of the patients with TG, supporting an antibody-mediated
(humoral) alloreactive mechanism of tissue injury in TG in a
subset of patients, as suggested by previous studies. However,
despite the growing body of evidence in support of an
antibody-mediated mechanism, there are also some conflict-
ing data that not all cases of TG are antibody-mediated.
Vongwiwatana et al.14 showed C4d deposition only in 25% of
biopsies with TG. Furthermore, in protocol biopsies 10 years
after transplantation, 6 of 11 of the C4d-negative patients had
TG in absence of DSA.41 In another comprehensive study,
C4d was not correlated with TG among all patients.18
Corroborating these results, C4d deposition was absent in
half of the patients in our series as well. One possible
explanation of these conflicting data may be the presence of
C4d-negative antibody-positive TG associated with elevated
intragraft endothelial transcripts as recently described by
Sis et al.42,43 Another explanation may be that, in addition
to antibody-mediated TG, there is also alloantibody-inde-
pendent TG where chronic viral infections such as HCV may
have a role, as strongly suggested by our observations.
Interestingly, in the 12 TG patients where DSA testing was
available, 89% of HCVTG patients had circulating DSA as
compared with none in the HCVþTG patients.
Various pathogenetic mechanisms may be postulated for
this link between HCV and TG. First, immune complexes
containing HCV, with or without cryoglobulins, may deposit
Table 2 | Clinical features and outcome of patients with TG
HCVTG (n=16) HCV+TG (n=9) P-value
Time from Tx to Bx (months) 124.3±117.0 61.0±46.2 0.07
Creatinine at Bx (mg/dl) 4.3±2.3 (median 3.4) 4.6±1.9 (median 3.8) 0.74
Proteinuria at Bx (g/24 h)a 2.6±1.1 2.3±2.3 0.73
Elevated liver transaminases (%) 0 4 (44%) 0.01
Total graft loss (%) 16 (100%) 9 (100%) 1.00
Death-censored graft loss (%) 15 (94%) 9 (100%) 1.00
Time from Bx to total graft loss (months) 29.4±34.9 10.1±15.8 0.07
Time from Tx to total graft loss (months) 153.7±120.5 71.1±52.7 0.03
Death (%) 1 (6%) 1 (11%) 1.00
Abbreviations: Bx, biopsy; HCV, hepatitis C virus; TG, transplant glomerulopathy; Tx, transplantation.






























Figure 2 |Kaplan–Meier curves showing time to graft loss after
transplantation in HCVTG and HCVþTG patients. HCVþTG
patients had a significantly faster progression to graft failure after
Tx as compared with HCVTG patients. HCV, hepatitis C virus;
TG, transplant glomerulopathy; Tx, transplantation.
Table 3 |Multivariate analysis of clinicopathological factors







C4d 0.82 (P=0.36) 1.86 (P=0.17)
TMA 0.14 (P=0.71) 0.29 (P=0.59)
HCV 4.56 (P=0.03) 5.06 (P=0.02)
Abbreviations: HCV, hepatitis C virus; TMA, thrombotic microangiopathy.
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within the glomeruli similar to native kidneys.26,27,29 After
transplantation, owing to immunosuppression, enhanced
viral replication in combination with modulation of
lymphocyte activity may produce an antigen–antibody
imbalance, which may predispose to the development of
de novo glomerular lesions in the allograft. Cryoglobulin
detection can be difficult in transplant patients, possibly
because of the immunosuppressive therapy that may reduce
the cryoglobulin level and/or alter the antigen–antibody
ratio.30,31 Even undetectable levels of cryoglobulins may be
of pathogenic significance after kidney transplantation and
may lead to absence of their extrarenal manifestations and
attenuated histological expression on the allograft in a
subgroup of HCVþ patients.30 Therefore, it may be difficult
to distinguish clearly between TG and MPGN in these cases.
Second, HCV infection may promote TG in some patients by
increasing humoral immune alloreactivity against the donor
tissue, suggesting an antibody-mediated process. This is
supported by our finding of C4d positivity in about one-
third of HCVþ cases and the presence of other features of
CHR such as PTC basement membrane multilayering and
presence of mononuclear cells in PTC and glomeruli in some
HCVþ patients even in the absence of C4d deposition. Last
but not the least, approximately one-third of patients with
TG had evidence of TMA in their biopsies, which may be
postulated as another potential overlapping pathway for
development of TG. Of note, the majority of the TMA cases
were HCVþ and majority of HCVþ cases had TMA,
suggesting that these two entities are interrelated. HCV
infection may trigger TMA by virtue of mechanisms as
postulated for cytomegalovirus. These include increased
cytokine production (for example, interleukin-6 and inter-
feron-a and g) and vascular endothelial cell activation that
promotes alloreactivity.44,45
From these results, it is tempting to postulate that a
humoral mechanism is associated with TG in HCV patients
and an alloantibody-independent process such as TMA in
HCVþ patients. However, because of the limited DSA data in
our study, and presence of C4d deposits in one-third of the
HCVþTG patients, definite conclusions regarding this
possibility will require larger prospective studies. Whatever
the exact mechanism of association between HCV infection
and lesions of TG may be, the recognition of this association
is potentially important, as the high prevalence of HCV
infection among patients on dialysis and consequently in
kidney transplant recipients puts this population at an
increased risk for developing HCV-associated TG.46 Further-
more, we have shown HCV positivity to be associated with a
more rapid progression to graft failure compared with HCV
recipients. Evaluation for HCV infection is therefore
warranted in all patients who develop lesions of TG after
kidney transplantation.
Overall, it appears that a number of above described
pathogenetic mechanisms (that is, chronic antibody-
mediated rejection or CHR, HCV-associated de novo
glomerular lesions, and TMA) are involved in the pathogenesis
of TG and may operate simultaneously producing an overlap,
making it difficult to recognize the relative role of a single
factor. In future, more work will be needed to find specific
pathological markers that may differentiate these mecha-
nisms. Detection of HCV antigens in the glomeruli using
specific monoclonal antibodies would seem to be a useful
solution, but the results have been difficult to reproduce.28
Recently, glomerular C4d staining using a polyclonal anti-
C4d antibody has been suggested as a potential marker of
humoral immune responses in TG.47 However, those authors
did not look at the possible association of TG with HCV
infection in their series. It would be interesting to study
whether glomerular C4d deposition or endothelial gene
expression differ significantly in HCVþ and HCV patients
with lesions of TG.
The strengths of our study are a comprehensive investiga-
tion of multiple clinical and histopathological factors
including C4d testing and EM, exclusion of patients with
confounding diagnosis of immune complex glomerulone-
phritis, and long-term follow-up. But there are also some
limitations that deserve specific consideration. First, being a
retrospective analysis, it suffers from some of the inherent
limitations of this kind of study design. Second, the sample
size is small, limiting the power of the study. However, still a
statistically significant difference in the prevalence of HCV
between the TG and the chronic CNIT groups was obtained,
strongly suggesting a link between the two. Some caution is
warranted when interpreting the negative results of the study.
Third, DSA testing during the peri-biopsy period was not
performed in all patients, and the stored sera were not
available for a retrospective analysis in the remaining
patients. Furthermore, the DSA numbers may be biased, as
testing for DSA was done more frequently in C4dþ cases and
may have been possibly as a result of the positive C4d. Last
but not the least, according to the local practice of the
institution, the biopsies were performed only by indication
and not on a prospective protocol basis. However, the
indication for biopsies was not biased by the HCV status of
the patients, as many of the biopsies were performed before
the introduction of routine screening for HCV serology at
our institution and we retrospectively tested all the
pretransplant sera for the presence of HCV RNA.
In summary, TG is not a specific diagnosis, but rather a
pattern of pathological injury with at least three overlapping
causes including C4d-associated antibody-mediated rejec-
tion, TMA, and chronic HCV infection-associated glomeru-
lar lesions. It is important to distinguish between these
mechanisms, as they may have different prognostic and
therapeutic implications. Further larger, prospective studies
carefully looking at the association among TG, TMA, and
HCV infection utilizing protocol biopsies evaluating C4d
staining, EM, endothelial gene expression, and circulating
DSA analysis are required to confirm our findings. Early
diagnosis of TG and better understanding of its pathogenesis
may improve management and outcome of this deleterious
post-transplant complication.
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MATERIALS AND METHODS
The study was approved by the Institutional review board of the
Massachusetts General Hospital.
Kidney biopsy selection
We searched the database of the Department of Pathology for kidney
allograft biopsies performed between January 1990 and December 2000
for evaluation of chronic allograft dysfunction (typically a gradual and
progressive rise in creatinine over a 6-month to 1-year period and/or
proteinuria 4500mg/24h). Of a total of 209 such indication biopsies,
we identified 25 biopsies performed in 25 patients with lesions of TG, as
defined by light microscopy findings of 410% duplication of the
glomerular basement membranes of non-sclerotic glomeruli and
absence of immune complexes by IF and/or EM.2,20 For comparing
the prevalence of HCV infection, all patients with isolated bio-
psy-proven chronic CNIT (n¼ 29) from the same time period were
used as controls. Chronic CNITwas defined by the presence of arteriolar
peripheral nodular medial hyalinosis typically accompanied by inter-
stitial fibrosis and tubular atrophy on biopsy in patients receiving either
cyclosporine or tacrolimus. For pathological comparison, the biopsies
from 14 cases of MPGN in native kidneys (7 HCVþ and 7 HCV) from
the same period were also identified. All biopsies with the diagnosis
of de novo or recurrent MPGN or other glomerular diseases including
diabetic nephropathy were excluded from the study.
Clinical data and donor-specific human leukocyte antigen
antibody
Clinical and laboratory data including peri-biopsy DSA analysis
were reviewed for all patients with TG (n¼ 25). Allograft loss
was defined as development of end-stage renal disease requiring
dialysis or death with a functioning graft. The pretransplant sera
of all patients were checked for presence of HCV RNA by reverse
transcriptase PCR using the Roche Amplicor 2.0 (Roche Molecular
Diagnostics, Branchburg, NJ). The sera had been stored at 80 1C in
the Tissue Typing Laboratory. Testing for circulating DSA in peri-
biopsy period was available in 12/25 TG patients (9 HCV and
3 HCVþ ). Cytotoxic cross-matches were performed using patient
sera against donor mononuclear cells that had been stored at
80 1C. T and B cells were isolated at the time of cross-matching
using immunomagnetic beads. Both antihuman globulin-enhanced
T-cell and standard complement-dependent cytotoxicity B-cell
assays were used.12
Pathology and tissue processing
Samples were routinely divided and processed in a standard fashion
to perform light microscopy, direct IF, and EM evaluation as
described earlier.48–50 Humoral antidonor reactivity was evaluated
retrospectively using a three-step IF technique for C4d deposition
in PTC in all available frozen biopsy samples.51 It could be
performed in all patients with TG, 23/29 controls with CNIT, and
all 14 additional native MPGN controls. EM study of glomeruli
was available in 23/25 patients with TG (7/9 HCVþ and 16/16
HCV patients), 6/23 controls with chronic CNIT, and all 14 native
MPGN cases. EM study for PTC basement membrane multilayering
was available only in 12/25 TG cases (3 C4dþ HCVþ, 6 C4dþ
HCV, 1 C4d HCVþ, and 2 C4d HCV) and in 6/29 chronic
CNIT cases; as this being a retrospective analysis, the EM sections
were not specifically prepared for evaluation of PTC in the earlier
biopsies.
All biopsies of 25 TG cases and other biopsies that these patients
had before the diagnosis of TG, 29 CNIT and 14 native kidney
MPGN cases were reviewed again. The glomerular lesions of TG
were analyzed systematically and scored by two observers inde-
pendently without the knowledge of clinical or serological data.
In addition to the required features of TG to be included in this
study, the biopsies were specifically analyzed for mesangial
hypercellularity, the presence/margination of inflammatory cells
(mononuclear cells) in glomeruli (21/25 cases), and PTC (20/25
cases). The remaining cases had no sufficient material available for
analysis. On the basis of the evaluation of 3–5 PTC per biopsy, PTC
basement membrane multilayering was categorized as absent, if no
or focal splitting of the BM was noted, or present, if three or more
layers of BM were identified. We also looked for evidence of TMA in
all biopsies. TMA was recognized by the presence of thrombi or
mucoid intimal thickening in arteries/arterioles or red blood cell
fragments in the walls of arteries/arterioles.
Statistical analysis
Statistical analysis and hierarchical clustering was conducted in SAS
JMP version 8.0 (SAS Institute, Cary, NC). Continuous variables are
expressed as mean±standard deviation, and categorical variables
are presented as proportions. Comparisons between groups were
done using Fisher’s exact test for categorical variables, unpaired
t-test for normally distributed, and Wilcoxon sum-rank test for non-
normally distributed continuous variables. Two-sided P-values
o0.05 were considered significant. The survival curves were
calculated by Kaplan–Meier survival analyses and compared by the
log-rank and Wilcoxon tests. Multivariate analysis was conducted to
analyze the influence of the presence of C4d, TMA, and HCV on
censored survival data for progression to graft failure using two
different methods: a Cox (semiparametric) proportional hazards
method and parametric (linear) iterative maximum likelihood
survival method using a Weibull distribution.52
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